部份中文Depo-Provera处方资料（仅供参考） 狄波-普维拉（药品商标名：Depo-Provera）是一种仅含孕激素的避孕药，即长效醋酸甲羟孕酮（通用药名：depot medroxyprogesterone acetate，DMPA），一种长效可逆激素避孕药物，仅需每3个月注射一次。这是一种含有17α-羟孕酮衍生progestin醋酸甲羟孕酮的用于长效注射的悬浊液。 药品名称 狄波 - 普维拉注射液Depo-Provera 性状: 醋酸甲羟孕酮的化学名为17-α-羟基-6-α-甲基孕酮醋酸酯。 本品为无菌水性混悬注射剂，除醋酸甲羟孕酮外，还含有聚乙二醇3350，多聚山梨醇酸酯80，氯化钠，羟基甲酸甲酯，羟基甲酸丙酯，注射用水。 药理作用 醋酸甲羟孕酮是一种孕激素，它是孕酮的衍生物。本品是一种没有雌激素活性的孕激素制剂，它的雄激素作用几乎没有。一定量的本药可抑制垂体分泌促性腺激素从而阻止卵泡成熟，造成育龄妇女停止排卵。 一定量的本药可抑制男性莱迪希细胞(Leydig Cell)的功能，即抑制内源性睾丸酮的产生。 口服醋酸甲羟孕酮也可对宫颈粘膜产生典型的孕酮变化(无羊齿样结晶)，并在阴道上皮的成熟指数方面增加中介细胞数。本药对激素依赖性癌症的抗癌活性在药理剂量下是依赖于其对下丘脑-垂体-性腺轴的作用，以及对雌激素受体及激素在组织水平上代谢的影响。 与孕酮相似，醋酸甲羟孕酮会产热，使用治疗某些癌症的大剂量(每天大于500 mg)时，则会出现皮质类固醇样作用。 药代动力学 肌注醋酸甲羟孕酮后，药物缓慢持续低水平释放，大约4-20天血浓度达到高峰，肌注后7-9个月仍可从血中检测到醋酸甲羟孕酮。醋酸甲羟孕酮的蛋白结合率为90-95%，分布容积为20±3升，它可以通过血脑屏障并可经乳汁分泌。尽管醋酸甲羟孕酮有许多代谢产物，但尚不能对它们明确定量，消除半衰期为6周，它主要经胆汁由粪便排泄，大约44%的原型药物由尿液排出。 适应症 避孕(抑制排卵)；治疗子宫内膜异位；治疗更年期血管舒缩症状；作为复发和/或转移性子宫内膜癌或肾癌的辅助和/或姑息疗法；治疗绝经妇女激素依赖性、复发性乳癌。 用法用量 避孕(抑制排卵) 150mg/次，每3个月深部肌注1次。首次注射应在正常自发月经的头5天之内使用；产后不哺乳妇女产后5日之内即可使用；产后哺乳妇女在产后6周或之前均可使用。 子宫内膜异位 每周50mg或每2周100mg肌注1次，至少进行6个月疗程。 更年期血管舒缩症状 每3个月150 mg深部肌注1次。 子宫内膜癌及肾癌 初始剂量为每周肌注400-1000mg，如果数周或数月内病情改善并稳定，每月维持剂量400mg就可保持此状况。 乳癌 肌注持续28天，每天500mg， 然后采用病人能反应的维持剂量，每周2次，每次500mg。 任何疑问，请遵医嘱！ 不良反应 过敏和类过敏性反应； 血栓栓塞症－血栓性静脉炎和肺栓塞； 中枢神经系统 - 紧张、失眠、嗜睡、疲倦、抑郁、眩晕和头痛； 皮肤和粘模 - 荨麻疹，瘙痒、红疹、痤疮、多毛和脱发； 胃肠道 - 恶心； 乳房 - 肿胀和溢乳； 其他 - 发热，体重变化和满月脸。 禁忌症 已知对醋酸甲羟孕酮或其它成分过敏的病人禁用。 注意事项 使用本药前，应对病情作一个评估，评估应排除生殖器官或乳房恶性肿瘤的存在，但对于治疗子宫内膜癌、乳癌或肾癌，以上表述不适用。 尽管尚无本药使用可造成血栓异常的报告，但如发现病人在使用本药中出现此方面的征兆，继续使用前应仔细权衡病情和治疗的需要。 大剂量醋酸甲羟孕酮使用尤其可造成体重增加及体液潴留。对于那些有此症状的病人可能会加重体重增加及体液潴留状况，故应注意。 大剂量醋酸甲羟孕酮在治疗癌症时，有时会出现类柯兴氏综合症，如满月脸、体液潴留，糖不耐受及血压升高。 低剂量醋酸甲羟孕酮对有些病人可能会降低糖耐量，其机理未知。尤其在治疗糖尿病患者时应注意。 有精神抑郁史的病人，接受本药治疗时应严密监测，有些病人会出现类似于经前期抑郁症的情况。 使用本药的病人，当需做子宫内膜或子宫颈组织病理检查时，应告诉病理检验师。 单剂或多剂量使用本药，其长期的抑制排卵作用可造成闭经和/或月经紊乱。 本药的使用会对下列实验室检验有影响：促性腺激素，血浆孕酮浓度，尿雌二醇浓度，血浆睾丸酮浓度(男性)，血浆雌激素浓度(女性)，血浆考的松浓度，糖耐量试验，甲吡酮试验(Metyrapone)。 孕妇及哺乳期妇女用药 不建议怀孕妇女使用孕激素类制剂。 本药用于哺乳期妇女，虽然能在乳汁中分泌，但含量很低。至今没有观察到任何影响婴儿发育的不良作用。 药物相互作用 合用氨基苯乙哌啶酮可显著地降低本药的生物利用度。 用药须知 在使用前，充分振摇以保证混悬液均匀。 生产厂家: Pfizer Depo-Provera 150 mg/ml Suspension for InjectionMedroxyproges 1. NAME OF THE MEDICINAL PRODUCT Depo-Provera 150 mg/ml Suspension for Injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each pre-filled syringe contains 1ml of suspension containing 150mg medroxyprogesterone acetate. For excipients, see 6.1. 3. PHARMACEUTICAL FORM Suspension for injection. White, sterile, aqueous suspension. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications As a progestogen, for parenteral administration: Contraception Depo-Provera is indicated for contraception. Depo-Provera may also be used for short-term contraception in the following circumstances: i. For partners of men undergoing vasectomy, for protection until the vasectomy becomes effective. ii. In women who are being immunised against rubella, to prevent pregnancy during the period of activity of the virus. iii. In women awaiting sterilisation. Since loss of bone mineral density (BMD) may occur in females of all ages who use MPA injection long-term (See section 4.4 Special warnings and special precautions for use), a risk/benefit assessment, which also takes into consideration the decrease in BMD that occurs during pregnancy and/or lactation, should be considered. It is of the greatest importance that adequate explanations of the long-term nature of the product, of its possible side-effects and of the impossibility of immediately reversing the effects of each injection are given to potential users and that every effort is made to ensure that each patient receives such counselling as to enable her to fully understand these explanations. Patient information leaflets are supplied by the manufacturer. It is recommended that the doctor uses these leaflets to aid counselling of the patient. Consistent with good clinical contraceptive practice a general medical as well as gynaecological examination should be undertaken before administration of Depo-Provera and at yearly intervals thereafter. 4.2 Posology and method of administration The sterile aqueous suspension of Depo-Provera should be vigorously shaken just before use to ensure that the dose being given represents a uniform suspension of Depo-Provera. Doses should be given by deep intramuscular injection into the gluteal muscle. Contraception All potential users of Depo-Provera should have a negative pregnancy test before first administration. Because of the risk of heavy or prolonged bleeding in some women, the drug should be used with caution in the puerperium. The recommended dose is 150 mg of MPA injectable suspension every 3 months administered by intramuscular injection in the gluteal muscle. The initial injection should be given during the first 5 days after the onset of a normal menstrual period; within 5 days postpartum if not breast-feeding; or, if exclusively breast-feeding, at or after 6 weeks postpartum. For second and subsequent injections, if the time interval between IM injections is greater than 13 weeks, pregnancy should be ruled out before administering the next IM injection. As with other hormonal contraceptives, regular consideration should be given to whether the previous treatment has resulted in: first-time migraine or unusually severe headaches, visual disturbances, reappearance of depression, pathological changes in liver function tests. Use in Children and Adolescents MPA IM is not indicated before menarche. Data regarding the effects of MPA on BMD in adolescent females (12-18 years) is available (see section 5.1 Pharmacodynamic Properties). Other than concerns about loss of BMD, the safety and effectiveness of MPA IM are expected to be the same for postmenarcheal adolescent and adult females. Switching from other Methods of Contraception When switching from other contraceptive methods, (MPA IM or SC) should be given in a manner that ensures continuous contraceptive coverage based upon the mechanism of action of both methods, (e.g., patients switching from oral contraceptives should have their first injection of MPA within 7 days after taking their last active pill). Hepatic Insufficiency No clinical studies have eva luated the effect of hepatic disease on the pharmacokinetics of MPA. However, MPA is almost exclusively eliminated by hepatic metabolism and steroid hormones may be poorly metabolized in patients with severe liver insufficiency, (see Section 4.3 - Contraindications). Renal Insufficiency No clinical studies have eva luated the effect of renal disease on the pharmacokinetics of MPA. However, since MPA is almost exclusively eliminated by hepatic metabolism, no dosage adjustment should be necessary in women with renal insufficiency. 4.3 Contraindications Depo-Provera is contraindicated in patients with a history of, or existent thrombo-embolic disorders; or at the above dosage with breast or genital cancer (known or suspected to be oestrogen dependent); and in patients with a known sensitivity to medroxyprogesterone acetate or any ingredient of the vehicle. Its use is contra-indicated in patients with impaired liver function or with active liver disease, and in patients with undiagnosed, vaginal bleeding. Depo-provera is contraindicated in patients with severe liver dysfunction Depo-Provera should not be used during known or suspected pregnancy, either for diagnosis or therapy. 4.4 Special warnings and precautions for use Warnings: Loss of Bone Mineral Density (BMD) Use of DMPA injection reduces serum estrogen levels and is associated with significant loss of BMD as bone metabolism accommodates to a lower estrogen level. Bone loss is greater with increasing duration of use, however BMD appears to increase after Depo-provera is discontinued and ovarian estrogen production increases. This loss of BMD is of particular concern during adolescence and early adulthood, a critical period of bone accretion. It is unknown if use of Depo-Provera by younger women will reduce peak bone mass and increase the risk for fracture in later life. (see Section 5.1 – Pharmacodynamic Properties, Clinical Studies; Bone Mineral Density Studies). Bone Fracture In one study (UK retrospective GPRD cohort study) an increased risk of fracture was seen following use of DPMA compared with non-DPMA users. However the extent to which this effect was due to DPMA or other lifestyle factors is unclear. DMPA injection should only be used as a long-term (e.g., longer than 2 years) birth control method if other birth control methods are unsuitable. BMD should be eva luated when a female needs to continue to use DMPA injection long term. In adolescent females, interpretation of BMD results should take into account patient age and skeletal maturity. Other birth control methods should be considered in the risk/benefit analysis for the use of DMPA injection in women with osteoporotic risk factors. DMPA injection can pose an additional risk in patients with risk factors for osteoporosis (e.g., metabolic bone disease, chronic alcohol and/or tobacco use, anorexia nervosa, strong family history of osteoporosis or chronic use of drugs that can reduce bone mass such as anticonvulsants or corticosteroids). It is recommended that all patients have adequate calcium and Vitamin D intake. For further information on BMD changes in both adult and adolescent females, as reported in recent clinical studies, refer to section 5.1 (Pharmacodynamic Properties) Menstrual Irregularity Prolonged anovulation with amenorrhoea and/or erratic menstrual patterns may follow the administration of either a single or multiple contraceptive doses of Depo-Provera. Unexpected vaginal bleeding during therapy with DMPA should be investigated. Return to fertility Women should be counselled that there is a potential for delay in return to full fertility following use of Depo-Provera. The median time to conception for those who do conceive is 10 months following the last injection with a range of 4 to 31 months and is unrelated to the duration of use. Cancer risks Studies in animals have indicated that administration of very high doses of oestrogens and/or progestogens will induce neoplastic tumours in some animal species. Studies in animals, in particular the dog, have demonstrated that the progestogens including progesterone will induce neoplastic mammary tumours. Recent investigations suggest that results of dosing studies with progestogen in the dog are irrelevant to the potential for such effects in human beings, because of differences in mammary receptor susceptibility and response. Long-term case-controlled surveillance of Depo-Provera users found no overall increased risk of ovarian, liver, or cervical cancer and a prolonged, protective effect of reducing the risk of endometrial cancer in the population of users. A meta-analysis in 1996 from 54 epidemiological studies reported that there is a slight increased relative risk of having breast cancer diagnosed in women who are currently using hormonal contraceptives. The observed pattern of increased risk may be due to an earlier diagnosis of breast cancer in hormonal contraceptive users, biological effects or a combination of both. The additional breast cancers diagnosed in current users of hormonal contraceptives or in women who have used them in the last ten years are more likely to be localised to the breast than those in women who never used hormonal contraceptives. Breast cancer is rare among women under 40 years of age whether or not they use hormonal contraceptives. In the meta-analysis the results for injectable progestogens (1.5% of the data) and progestogen only pills (0.8% of the data) did not reach significance although there was no evidence that they differed from other hormonal contraceptives. Whilst the background risk of breast cancer increases with age, the excess number of breast cancer diagnoses in current and recent injectable progestogen (IP) users is small in relation to the overall risk of breast cancer, possibly of similar magnitude to that associated with combined oral contraceptives. However, for IPs, the evidence is based on much smaller populations of users (less than 1.5% of the data) and is less conclusive than for combined oral contraceptives. It is not possible to infer from these data whether it is due to an earlier diagnosis of breast cancer in ever-users, the biological effects of hormonal contraceptives, or a combination of reasons. The most important risk factor for breast cancer in IP users is the age women discontinue the IP; the older the age at stopping, the more breast cancers are diagnosed. Duration of use is less important and the excess risk gradually disappears during the course of the 10 years after stopping IP use, such that by 10 years there appears to be no excess. The evidence suggests that compared with never-users, among 10,000 women who use IPs for up to 5 years but stop by age 20, there would be much less than 1 extra case of breast cancer diagnosed up to 10 years afterwards. For those stopping by age 30 after 5 years use of the IP, there would be an estimated 2-3 extra cases (additional to the 44 cases of breast cancer per 10,000 women in this age group never exposed to oral contraceptives). For those stopping by age 40 after 5 years use, there would be an estimated 10 extra cases diagnosed up to 10 years afterwards (additional to the 160 cases of breast cancer per 10,000 never-exposed women in this age group). It is important to inform patients that users of all hormonal contraceptives appear to have a small increase in the risk of being diagnosed with breast cancer, compared with non-users of hormonal contraceptives, but that this has to be weighed against the known benefits. Patients receiving treatment with progestogens should be kept under regular surveillance. A very low incidence of anaphylactoid reactions has been reported. Patients with a history of endogenous depression should be carefully monitored. Some patients may complain of premenstrual-type depression while on Depo-Provera therapy. Precautions: Medication should not be re administered pending examination if there is a sudden partial or complete loss of vision or if there is a sudden onset of proptosis, diplopia, or migraine, jaundice or pathological changes in liver function tests. If examination reveals papilledema or retinal vascular lesions, medication should not be re administered. A decrease in glucose tolerance has been observed in some patients treated with progestogens. The mechanism for this decrease is obscure. For this reason, diabetic patients should be carefully observed while receiving progestogen therapy. Rare cases of thrombo-embolism have been reported with use of Depo-Provera. Should the patient experience pulmonary embolism, cerebrovascular disease or retinal thrombosis while receiving Depo-Provera, the drug should not be re administered. Physicians should be aware that pathologists should be informed of the patient's use of Depo-Provera if endometrial or endocervical tissue is submitted for histologic examination. The results of certain laboratory tests may be affected by the use of Depo-Provera. These include plasma/urinary gonadotrophin levels (e.g. LH and FSH), plasma progesterone levels, urinary pregnanediol levels, plasma oestrogen levels (in the female), plasma cortisol levels, glucose tolerance test, metyrapone test, liver function tests, thyroid function tests and sex hormone binding globulin. Coagulation test values for prothrombin (Factor II), and Factors VII, VIII, IX and X may increase. The effects of medroxyprogesterone acetate on lipid metabolism have been studied with no clear impact demonstrated. Both increases and decreases in total cholesterol, triglycerides, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol have been observed in studies. The drug should be used with caution in patients with cardiovascular or renal disease, asthma or epilepsy because of the potential problem of fluid retention in some patients. Weight gain There is a tendency for women to gain weight while on Depo-Provera therapy. Studies indicate that over the first 1-2 years of use, average weight gain was 5-8 lbs. Women completing 4-6 years of therapy gained an average of 14-16.5 lbs. There is evidence that weight is gained as a result of increased fat and is not secondary to an anabolic effect or fluid retention. As with any intramuscular injection, especially if not administered correctly, there is a risk of abscess formation at the site of injection, which may require medical or surgical intervention. Theoretical evidence suggests that use of progesterones should be interrupted for an interval to permit return to normal hypothalamo-pituitary-gonadal function. While it is not yet possible to state even a provisionally acceptable interval, any prescriber should bear this matter in mind when organising prolonged use of such agents. As this product contains methylparahydroxbenzoate and propylparahydroxybenzoate, it may cause allergic reactions (possibly delayed), and exceptionally, bronchospasm. 4.5 Interaction with other medicinal products and other forms of interaction Aminoglutethimide administered concurrently with Depo-Provera may significantly depress the bioavailability of Depo-Provera. Users of high-dose MPA should be warned of the possibility of decreased efficacy with the use of aminoglutethimide. Interactions with other medicinal treatments (including oral anticoagulants) have rarely been reported, but causality has not been determined. The possibility of interaction should be borne in mind in patients receiving concurrent treatment with other drugs. 4.6 Pregnancy and lactation MPA is contraindicated in women who are pregnant. Some reports suggest an association between intrauterine exposure to progestational drugs in the first trimester of pregnancy and genital abnormalities in male and female fetuses. Infants from unintentional pregnancies that occur 1-2 months after injection of MPA injectable suspension may be at an increased risk of low birth weight, which, in turn, is associated with an increased risk of neonatal death. The attributable risk is low because pregnancies while on MPA are uncommon. If MPA is used during pregnancy, or if the patient becomes pregnant while using this drug, the patient should be appraised of the potential hazard to the fetus. Children exposed to medroxyprogesterone acetate in utero and followed to adolescence, showed no evidence of any adverse effects on their health including their physical, intellectual, sexual or social development. Lactation MPA and its metabolites are excreted in breast milk. There is no evidence to suggest that this presents any hazard to the nursing child. Infants exposed to medroxyprogesterone via breast milk have been studied for developmental and behavioural effects to puberty. No adverse effects have been noted. 4.7 Effects on ability to drive and use machines Not applicable. 4.8 Undesirable effects Patients receiving Depo-Provera may be subject to the side-effects normally associated with the use of progestogens. In addition, it is likely that some or all of the following effects may occur: Genitourinary Delay in return to normal menstrual cycling and transient infertility lasting up to 18 months or occasionally longer may occur following continuous treatment with Depo-Provera. i. Depo-Provera may be expected to cause disruption of the normal menstrual cycle. Irregular, prolonged, decreased or heavy vaginal bleeding or spotting may be experienced during the first two or three cycles of treatment. The frequency of occurrence of bleeding usually decreases with subsequent injections. After one year of treatment some women are amenorrhoeic. *In postmarketing experience, there have been rare cases of osteoporosis including osteoporotic fractures reported in patients taking MPA IM. 4.9 Overdose No positive action is required other than cessation of therapy. 5. PHARMACOLOGICAL PROPERTIES 5.1 Pharmacodynamic properties Parenteral medroxyprogesterone acetate is a long acting progestational steroid. It exerts anti-oestrogenic, anti-androgenic and antigonadotrophic effects. BMD Changes in Adult Women In a controlled, clinical study adult women using MPA injection (150 mg IM) for up to 5 years showed spine and hip mean BMD decreases of 5-6%, compared to no significant change in BMD in the control group. The decline in BMD was more pronounced during the first two years of use, with smaller declines in subsequent years. Mean changes in lumbar spine BMD of –2.86%, -4.11%, -4.89%, -4.93% and -5.38% after 1, 2, 3, 4 and 5 years, respectively, were observed. Mean decreases in BMD of the total hip and femoral neck were similar. Please refer to Table 1 below for further details. After stopping use of MPA injection (150 mg IM), there was partial recovery of BMD toward baseline values during the 2-year post-therapy period. After 2 years off treatment, the BMD deficit had decreased to approximately 2.1% at the spine and hip. A longer duration of treatment was associated with a slower rate of BMD recovery (see Section 4.4 – Special warnings and precautions for use ). Table 1. Mean Percent Change from Baseline in BMD in Adults by Skeletal Site and Cohort after 5 Years of Therapy with Medroxyprogesterone acetate 150 mg IM and after 2 Years Post-Therapy or 7 Years of Observation (Control) *The treatment group consisted of women who received medroxyprogesterone acetate injection (150 mg IM) for 5 years and the control group consisted of women who did not use hormonal contraception for this time period. ** The treatment group consisted of women who received medroxyprogesterone acetate Injection (150 mg IM) for 5 years and were then followed up for 2 years post-use and the control group consisted of women who did not use hormonal contraceptive for 7 years. BMD Changes in Adolescent Females (12-18 years) An open-label non-randomized clinical study of MPA injectable (150 mg IM every 3 months for up to 240 weeks [4.6 years]) in adolescent females (12-18 years) for contraception also showed a significant decline in BMD from baseline. Among subjects who received > 4 injections/60-week period, the mean decrease in lumbar spine BMD was - 2.1 % after 240 weeks; mean decreases for the total hip and femoral neck were -6.4 % and -5.4 %, respectively. Based on mean changes, post-treatment follow-up showed that lumbar spine BMD recovered to baseline levels approximately 1 year after treatment was discontinued and that hip BMD recovered to baseline levels approximately 3 years after treatment was discontinued. In contrast, unmatched, untreated subjects showed mean BMD increases at 240 weeks of 6.4 %, 1.7 % and 1.9 % for lumbar spine, total hip and femoral neck, respectively. (see Section 4.4 – Special warnings and precautions for use). Bone fracture A retrospective cohort study using data from the General Practice Research Database (GPRD) reported that women using MPA injections (DMPA), have a higher risk of fracture compared with contraceptive users with no recorded use of DMPA (incident rate ratio 1.41, 95% CI 1.35-1.47 for the five year follow-up period); it is not known if this is due to DMPA, or to other related lifestyle factors which have a bearing on fracture rate. By contrast, in women using DMPA, the fracture risk before and after starting DMPA was not increased (relative risk 1.08, 95% CI 0.92-1.26). Importantly, this study could not determine whether use of DMPA has an effect on fracture rate later in life. 5.2 Pharmacokinetic properties The drug is absorbed readily, metabolised in the liver initially to progesterone which is rapidly distributed to binding sites, and to pregnanediol and excreted thereafter in urine. Absorption: Following intramuscular administration, MPA is slowly released, resulting in low, but persistent levels in the circulation. Immediately after intramuscular injection of 150mg/ml MPA, plasma levels were 1.7 ± 0.3 nmol/l. Two weeks later, levels were 6.8 ± 0.8 nmol/l. Mean time to peak is approximately 4 to 20 days following an intramuscular dose. Serum medroxyprogesterone acetate levels gradually decline and remain relatively constant at about 1 ng/ml for 2-3 months. Circulating levels can be detected for as long as 7 to 9 months following an intramuscular injection. Distribution: MPA is approximately 90 to 95 % protein bound. Volume of distribution is reported as 20 + 3 liters. Medroxyprogesterone acetate crosses the blood-brain-barrier, and the placental barrier. Low levels of medroxyprogesterone acetate have been detected in breast milk of lactating women administered 150 mg of medroxyprogesterone acetate by the IM route. Metabolism: MPA is metabolized in the liver. Elimination: The elimination half-life following single intramuscular injection is about 6 weeks. Medroxyprogesterone acetate is primarily excreted in the faeces, via biliary secretion. Approximately 30 % of an intramuscular dose is secreted in the urine after 4 days. 5.3 Preclinical safety data None stated 6. PHARMACEUTICAL PARTICULARS 6.1 List of excipients Methyl parahydroxybenzoate (E218) Macrogol Polysorbate 80 Propyl parahydroxybenzoate (E216) Sodium chloride Water for injections Sodium hydroxide Hydrochloric acid 6.2 Incompatibilities None stated. 6.3 Shelf life 3 Years. 6.4 Special precautions for storage Do not store above 25°C. Do not freeze. 6.5 Nature and contents of container 1ml pre-filled disposable syringe consisting of a Type I (Ph. Eur.) glass barrel with a butyl rubber stopper and tip cap containing 1 ml of suspension. 6.6 Special precautions for disposal and other handling Do not mix with other agents. For single use only. Discard any unused contents. 7. MARKETING AUTHORISATION HOLDER Pharmacia Ireland 9 Riverwalk National Digital Park Citywest Business Campus Dublin 24 8. MARKETING AUTHORISATION NUMBER(S) PA 936/38/1 9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION 19th January 1996/19th January 2006 10. DATE OF REVISION OF THE TEXT 6th October 2011 Ref DP 3_0